2025 ASCO GI 摘要标题公布！大会首日聚焦胃食管癌，超40项中国研究引领潮流

Efficacy and safety of albumin-bound docetaxel vs. docetaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma: A multicenter, randomized, phase II study.

白蛋白结合多西他赛对比多西他赛单药在既往接受过治疗的晚期胃或胃食管结合部腺癌患者中的疗效和安全性：一项多中心、随机、II 期研究

讲者：王志强    中山大学肿瘤防治中心

Conversion effects of PD-1 inhibitor camrelizumab (Cam) combined with Nab-POF regimen in patients (pts) with initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction adenocarcinoma: FDZL-001 trial 

PD-1抑制剂卡瑞利珠单抗（Cam）联合 Nab-POF 方案作为初始不可切局部晚期或局限性转移性胃或胃食管结合部腺癌患者的转化治疗：FDZL-001试验

讲者：耿其荣    复旦大学附属肿瘤医院 

Real world data and biomarker analysis of the efficacy and safety of PD-1 inhibitor combined with chemotherapy in first-line treatment of advanced gastric cancer      

讲者：Xiaoting Ma    中国医学科学院肿瘤医院   

Retreatment with immune checkpoint inhibitors (ICIs) for patients with advanced gastric cancer: A retrospective, real-world study   

讲者：Yong-Xu Jia    郑州大学第一附属医院

Nimotuzumab combined with chemotherapy plus immunotherapy as first-line treatment for advanced esophageal squamous cell carcinoma

讲者：Qi Wang    中国人民解放军总医院 

Prognostic analysis of pathological complete response after neoadjuvant therapy for locally advanced gastric cancer: A national, multicenter, retrospective study    

讲者：Jie Chen    复旦大学附属肿瘤医院 

Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exploratory study       

讲者：Xin Wang    中国医学科学院肿瘤医院

Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial    

讲者：Zhiwei Chang    郑州大学第一附属医院

Safety and efficacy of perioperative chemotherapy combined with PD-1 inhibitor versus chemotherapy with D2 gastrectomy plus PAND in gastric cancer with PALD metastasis: A single-center retrospective cohort study    

讲者：Zeyao Ye    浙江省肿瘤医院  

Envafolimab in combination with lenvatinib and albumin paclitaxel for previously treated advanced GEJ adenocarcinoma: Latest analysis of a phase II, two-cohort study    

讲者：XIAOYING ZHAO    复旦大学附属肿瘤医院    

An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma    

讲者：Yunyi Du    长治医学院附属长治人民医院

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649    

讲者：沈琳    北京大学肿瘤医院   

Does chemotherapy regimen matter for first-line immunochemotherapy in low programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC)? A systemic review and meta-analysis   

讲者：Jhe-Cyuan Guo    台湾大学癌症中心

Perioperative chemotherapy with either S-1 or 5-fluorouracil plus oxaliplatin and docetaxel for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective trial and matched comparison   

讲者：Chih Chieh Yen    台湾成功大学

PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial    

讲者：Fei Ma    郑州大学附属肿瘤医院 

A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results        

讲者：Min Jin    华中科技大学同济医学院附属协和医院

Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial        

讲者：Chengixn Liu    山东省肿瘤医院

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Survival results of a phase II trial     

讲者：yi wang    山东大学齐鲁医院

Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306     

讲者：Yi Li    中国人民解放军总医院

Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: A post hoc analysis of RATIONALE-305 study   

讲者：邱妙珍    中山大学肿瘤防治中心

Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study    

讲者：Liang Dai    北京大学肿瘤医院

Updated results from the phase Ib/II study of fruquintinib combined with SOX and toripalimab in patients with advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC)

讲者：Xiangrui Meng    郑州大学第一附属医院

An organ-preserving strategy in patients with esophageal squamous cell carcinoma treated with immunochemotherapy

讲者：Bo Zhang    中国医学科学院肿瘤医院

Transarterial infusion chemotherapy and embolization (TAICE) as a pre-operative therapy for patients with locally advanced gastric cancer (LAGC): A prospective, single-arm, pilot study    

讲者：Zheng Liu    复旦大学附属中山医院

Chemoimmunotherapy plus radiotherapy in advanced esophageal squamous-cell carcinoma   

讲者：Keke Nie    青岛市中心医院

HLX22 plus trastuzumab and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): Updated results with additional patients      

讲者：李进   中国药科大学附属上海高博肿瘤医院

Paclitaxel oral solution versus paclitaxel injection as a second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial    

讲者：李进   中国药科大学附属上海高博肿瘤医院

Neoadjuvant adebrelimab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: A phase 2 trial   

讲者：Zhigang Li    上海交通大学医学院附属胸科医院 

Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trial    

讲者：Yong-Xu Jia    郑州大学第一附属医院

Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial    

讲者：Yanhong Gu    江苏省人民医院

Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): OS analysis results of the SYLT-023        

讲者：Liyu Su    福建医科大学肿瘤医院

Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma from a phase Ib/II study   

讲者：彭智    北京大学肿瘤医院

Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II clinical trial (ALTER-E005) 

讲者：Changying Guo    江西省肿瘤医院

Clinical study of radiotherapy combined with tegafur bolus synchronization in the treatment of inoperable elderly middle and advanced esophageal cancer      

讲者：Xixi Zhao   西安交通大学第二附属医院

Fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): A single-arm, open-label phase 2 study    

讲者：Chenchen Wang    复旦大学附属肿瘤医院

Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from an open-label, multicenter phase II trial (AK104-IIT-014)   

讲者：Wang Qu    中国医学科学院肿瘤医院

Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia    

讲者：CHIA JUI YEN    台湾成功大学

Unraveling the role of interferon-stimulated neutrophils: A promising biomarker for immunotherapy efficacy and prognosis in gastric adenocarcinoma        

讲者：Hongda Pan    复旦大学附属肿瘤医院

Effect of tRF-28-ZJ47D112Z4DZ on the pathogenesis of gastric cancer through targeting cyclin D1/CDK4 and its early diagnostic value   

讲者：Yu Xiuchong    宁波大学附属第一医院

Use of nucleotyping and tumor stroma ratio to predict prognosis in patients with resected intestinal-type gastric cancer  

讲者：Dan Sha    山东第一医科大学附属省立医院

Histopathological growth patterns of gastric cancer liver metastasis and their association with patient prognosis       

讲者：Dan Sha    山东第一医科大学附属省立医院